The Effect of Preoperative Gabapentin on Postoperative Pain Control and Analgesic Requirements Following Bariatric Surgery

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07169006

Enrollment

102

Registered

2025-09-11

Start date

2026-01-01

Completion date

2026-12-01

Last updated

2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery Analgesia

Brief summary

The importance of bariatric anesthesia and analgesia research cannot be ignored as it can inform and improve the perioperative protocols for other patients with morbid obesity irrespective of the surgical procedures they are undergoing

Detailed description

Among various postoperative complications, pain is the main adverse event experienced by patients. Good control of postoperative pain is an important factor for reducing early postoperative complications such as pulmonary embolism, deep vein thrombosis, ileus, and respiratory infections, and for decreasing length of stay, lowering costs, and increasing patient satisfaction

Interventions

DRUGGroup 1

Will receive a single dose of gabapentin 300 mg preoperatively before standard general anesthesia

DRUGGroup 2

will receive a placebo before standard general anesthesia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Masking description

Single

Intervention model description

Assuming an effect size of 0.5 for preoperative gabapentin, a sample of 51 patients in each group would be enough to detect such effect, if true, at 0.05 alpha error and 0.80 power of the test

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with American Society of Anesthesiologists physical status ASA I to III * both genders * Morbid obese scheduled for bariatric surgery

Exclusion criteria

* patients with impaired liver or kidney disease * patients with history of hypersensitivity to gabapentin * patients with history of alcohol abuse, chronic pain or frequent use of analgesic * patients with uncontrolled medical disease

Design outcomes

Primary

Measure	Time frame	Description
Comparing pain score between the two groups during 1st postoperative 24 hours using visual analogue score (VAS	24 hours postoperative	Comparing pain score between the two groups during 1st postoperative 24 hours using visual analogue score (VAS

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026